Abalos Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$49M
- Investors
-
8
Abalos Therapeutics General Information
Description
Developer of an immuno-virotherapy platform designed to facilitate the treatment of solid tumors. The company's technology utilizes arenaviruses, viral replication, and systemic administration to provide innate immune activation, adaptive response triggering, and tumor uncloaking, enabling oncology patients to combat primary tumors and distant metastases through a concerted immune system attack from within the tumor.
Contact Information
Website
www.abalos-tx.comCorporate Office
- Merowingerplatz 1 A
- 40225 Dusseldorf
- Germany
Corporate Office
- Merowingerplatz 1 A
- 40225 Dusseldorf
- Germany
Abalos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 14-Oct-2021 | $49M | Completed | Pre-Clinical Trials |
Abalos Therapeutics Comparisons
Industry
Financing
Details
Abalos Therapeutics Competitors (2)
One of Abalos Therapeutics’s 2 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
Abalos Therapeutics Patents
Abalos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026185313-A1 | Virus particles for the treatment of cancer | Pending | 05-Mar-2025 | ||
| AU-2024330299-A1 | Virus particles with improved entry into tumor cells | Pending | 31-Aug-2023 | ||
| EP-4771132-A1 | Virus particles with improved entry into tumor cells | Pending | 31-Aug-2023 | ||
| WO-2025046106-A1 | Virus particles with improved entry into tumor cells | Inactive | 31-Aug-2023 | ||
| AU-2022226407-A1 | New virus particles for therapeutic purposes | Pending | 26-Feb-2021 | C12N7/00 |
Abalos Therapeutics Signals
Abalos Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| Coparion | Venture Capital | Minority | ||
| Gründerfonds Ruhr | Venture Capital | Minority | ||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Hx Bio Ventures | Venture Capital | Minority |
Abalos Therapeutics FAQs
-
When was Abalos Therapeutics founded?
Abalos Therapeutics was founded in 2019.
-
Where is Abalos Therapeutics headquartered?
Abalos Therapeutics is headquartered in Dusseldorf, Germany.
-
What is the size of Abalos Therapeutics?
Abalos Therapeutics has 23 total employees.
-
What industry is Abalos Therapeutics in?
Abalos Therapeutics’s primary industry is Drug Discovery.
-
Is Abalos Therapeutics a private or public company?
Abalos Therapeutics is a Private company.
-
What is the current valuation of Abalos Therapeutics?
The current valuation of Abalos Therapeutics is .
-
What is Abalos Therapeutics’s current revenue?
The current revenue for Abalos Therapeutics is .
-
How much funding has Abalos Therapeutics raised over time?
Abalos Therapeutics has raised $49M.
-
Who are Abalos Therapeutics’s investors?
Boehringer Ingelheim Venture Fund, Coparion, Gründerfonds Ruhr, High-Tech Gründerfonds, and Hx Bio Ventures are 5 of 8 investors who have invested in Abalos Therapeutics.
-
Who are Abalos Therapeutics’s competitors?
Agenus and Genetix Biotherapeutics are competitors of Abalos Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process